Charles Quick
Pulmonary Disease · Indianapolis, INNPI 1174527691
Payments from drug & device makers
Across 378 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$390
- Mylan Specialty L.p.$304
- Insmed, Inc.$291
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,36897%
- Education$2063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 85 | $1,164 |
| Boehringer Ingelheim | 66 | $1,155 |
| AstraZeneca(2 entities) | 66 | $1,050 |
| Regeneron Healthcare Solutions, Inc. | 13 | $390 |
| Mylan Specialty L.p. | 17 | $304 |
| Insmed, Inc. | 8 | $291 |
| Pfizer | 15 | $245 |
| Sanofi | 10 | $212 |
| Genentech USA, Inc. | 18 | $198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $194 |
| Sunovion Pharmaceuticals Inc. | 11 | $174 |
| Mallinckrodt Hospital Products Inc. | 4 | $156 |
| Philips North America LLC | 8 | $127 |
| Novartis | 7 | $124 |
| United Therapeutics Corporation | 6 | $112 |
| Amgen | 6 | $100 |
| Pulmonx Corporation | 1 | $95 |
| Shire North American Group Inc | 5 | $83 |
| AbbVie(2 entities) | 3 | $61 |
| Merck | 3 | $55 |
| Grifols USA, LLC | 3 | $51 |
| Circassia Inc. | 3 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $27 |
| Nabriva Therapeutics, PLC | 2 | $26 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$122
- TRELEGY ELLIPTA$118
- Arikayce$110
How this compares
$6,575 in reported general payments places this provider in the 65th percentile of 258 pulmonary disease providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $42,786 |
| EliquisApixaban | 33 | $26,621 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $20,137 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $18,098 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $17,818 |
| Spiriva RespimatTiotropium Bromide | 20 | $14,459 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $11,120 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,049 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 125 | $5,800 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,558 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,439 |
| Montelukast Sodium | 69 | $789 |
| Ventolin HfaAlbuterol Sulfate | 11 | $718 |
| Fluticasone Propionate | 20 | $373 |
| Prednisone | 40 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,164 | $74,04495 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $1,155 | $32,27849 claims |
| PfizerEliquis | $245 | $26,62133 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,050 | $24,14740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Indianapolis
- Cynthia BrownIndianapolis$7.3M
- Roberto MachadoIndianapolis$219K
- Michael DuncanIndianapolis$146K
- Gary ZalogaIndianapolis$79K
- Abboud KawakIndianapolis$68K
- Ryan LogueIndianapolis$30K
- George RubeizIndianapolis$24K
- Clare ProhaskaIndianapolis$20K
- Rajat NarangIndianapolis$17K
- Marcus TielkerIndianapolis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.